Unknown

Dataset Information

0

Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells.


ABSTRACT: Purpose:Paclitaxel (PTX) is a first-line chemotherapeutic agent for treating ovarian cancer. However, PTX resistance has become a major obstacle in ovarian cancer therapy. The underlying mechanism associated with PTX resistance is still unclear. Patients and Methods:We used qPCR to detect taurine up-regulated 1 (TUG1) expression in normal ovarian tissues and ovarian tumor tissues. A combination of small interfering RNA (siRNA), cell counting kit 8 (CCK8), colony formation assay and nude mouse model were used to detect the effect of TUG1 on ovarian cancer cell PTX-resistance. Autophagy/cytotoxicity dual staining assay, luciferase reporter assay, Western blot and RNA-binding protein immunoprecipitation assay were used for further mechanistic studies. Results:TUG1 is highly expressed not only in ovarian tumor tissues compared with normal ovarian tissues but also in the chemo-resistant group compared with the sensitive group. Knockdown of TUG1 by siRNA decreased ovarian cancer cell and xenograft tumor PTX resistance with or without PTX treatment. Moreover, deletion of TUG1 in ovarian cancer cells decreased autophagosome formation and increased apoptosis as demonstrated by autophagy/cytotoxicity dual staining and Western blot assays. Furthermore, microRNA-29b-3p (miR-29b-3p) was found as the direct target of TUG1. Additionally, TUG1 could directly bind Ago2, a key protein of the RNA-induced silencing complex. Conclusion:Our findings suggest that TUG1, through targeting miR-29b-3p, induces autophagy and consequently results in PTX resistance in ovarian cancer.

SUBMITTER: Gu L 

PROVIDER: S-EPMC7065918 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Long Noncoding RNA TUG1 Promotes Autophagy-Associated Paclitaxel Resistance by Sponging miR-29b-3p in Ovarian Cancer Cells.

Gu Lize L   Li Qing Q   Liu Hao H   Lu Xun X   Zhu Mingchen M  

OncoTargets and therapy 20200306


<h4>Purpose</h4>Paclitaxel (PTX) is a first-line chemotherapeutic agent for treating ovarian cancer. However, PTX resistance has become a major obstacle in ovarian cancer therapy. The underlying mechanism associated with PTX resistance is still unclear.<h4>Patients and methods</h4>We used qPCR to detect taurine up-regulated 1 (TUG1) expression in normal ovarian tissues and ovarian tumor tissues. A combination of small interfering RNA (siRNA), cell counting kit 8 (CCK8), colony formation assay an  ...[more]

Similar Datasets

| S-EPMC8649340 | biostudies-literature
| S-EPMC7137070 | biostudies-literature
| S-EPMC8560251 | biostudies-literature
| S-EPMC6556671 | biostudies-literature
| S-EPMC6378276 | biostudies-literature
| S-EPMC8194245 | biostudies-literature
| S-EPMC7695380 | biostudies-literature
| S-EPMC10902679 | biostudies-literature
| S-EPMC8335671 | biostudies-literature
| S-EPMC6692615 | biostudies-literature